Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001072613-25-000670·Adaptimmune Therapeutics PLC
Schedule 13D ownership disclosure
ADAPTIMMUNE THERAPEUTICS PLC
Ordinary Shares, (pound).001 par value per share · CUSIP: 00653A107
Event date: 2025-08-15
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- New Enterprise Associates 14, L.P.Reported CIK 0001544328
Shares: 4.00 · Class: 0%
- NEA Partners 14, L.P.Reported CIK 0001551531
Shares: 4.00 · Class: 0%
- NEA 14 GP, LTDReported CIK 0001551532
Shares: 4.00 · Class: 0%
- New Enterprise Associates 16, L.P.Reported CIK 0001694560
Shares: 4.00 · Class: 0%
- NEA Partners 16, L.P.Reported CIK 0001712881
Shares: 4.00 · Class: 0%
- NEA 16 GP, LLCReported CIK 0001712882
Shares: 4.00 · Class: 0%
- Forest BaskettReported CIK 0001277631
Shares: 4.00 · Class: 0%
- Anthony A. Florence, Jr.Reported CIK 0001559827
Shares: 4.00 · Class: 0%
- Patrick J. KerinsReported CIK 0001235112
Shares: 4.00 · Class: 0%
- Mohamad H. MakhzoumiReported CIK 0001630226
Shares: 4.00 · Class: 0%
- Scott D. SandellReported CIK 0001237289
Shares: 4.00 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001072613-25-000670
- Form type
- SCHEDULE 13D/A
- Filer
- Adaptimmune Therapeutics PLC
- CIK
- CIK 1621227
- Filed
- Aug 19, 2025
- Reporting period
- Aug 15, 2025
- Description
- Schedule 13D beneficial ownership